<DOC>
	<DOCNO>NCT00016302</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . This phase II trial study several different combination chemotherapy regimens see well work treat patient newly diagnose acute lymphoblastic leukemia</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine feasibility addition nelarabine modify multiagent Berlin-Frankfurt-Muenster-86 chemotherapy patient newly diagnose T-cell acute lymphoblastic leukemia . SECONDARY OBJECTIVES : I . Determine pharmacokinetics intracellular pharmacology nelarabine patient . OUTLINE : This pilot , multicenter study . Prednisone Response Pre-Induction : All patient receive oral prednisone three time daily day -7 -1 methotrexate intrathecally ( IT ) day -7* week 0 . Good prednisone responder proceed induction regimen A . Poor prednisone responder proceed induction regimen C. NOTE : *Patients receive cytarabine IT within week prior study entry receive methotrexate IT day -6 . Regimen A ( good prednisone responder ) ( closed 2/27/03 ) : Induction ( week 1-5 ) : Patients receive vincristine IV day 1 , 8 , 15 ; oral prednisone three time daily day 1-14 ; daunorubicin IV 15 minute day 1 , 8 , 15 , 22 ; asparaginase intramuscularly ( IM ) day 12 , 15 , 18 , 22 , 24 , 27 , 30 , 33 ; methotrexate IT day 1 . If bone marrow M1 , week 6 induction therapy begin day 36 peripheral blood count recover . If bone marrow M2 , patient begin week 6 induction therapy immediately . If bone marrow M3 , treatment discontinues . Those patient minimal residual disease ( MRD ) day 36 proceed regimen B . Induction ( week 6-9 ) : Patients receive cyclophosphamide IV 1 hour day 36 63 ; cytarabine IV 72 hour day 38-40 , 45-47 , 52-54 , 59-61 ; oral mercaptopurine daily day 36-63 ; methotrexate IT day 45 59 . Consolidation ( week 10-19 ) : Patients receive oral mercaptopurine day 64-119 ; methotrexate IV 24 hour leucovorin calcium IV , orally tolerate , day 71 , 85 , 99 , 113 ; methotrexate IT day 71 , 85 , 99 , 113 . ( Patients begin methotrexate blood count recover bone marrow M1 ) . Reinduction ( week 20-29 ) : Patients receive oral dexamethasone three time daily day 134-154 ; vincristine IV day 141 148 ; doxorubicin IV 15 minute day 134 , 141 , 148 , 155 ; asparaginase IM day 141 , 144 , 148 , 151 , 154 , 157 . Beginning day 169 blood count recover , patient receive cyclophosphamide IV day 169 , cytarabine IV 72 hour day 171-173 178-180 ; oral thioguanine daily day 169-182 ; methotrexate IT day 171 178 . Patients also receive cranial irradiation 10 day begin day 189 . Maintenance ( week 30-101 ) : Patients receive vincristine IV ; oral prednisone three time daily 5 day ; oral mercaptopurine daily ; oral methotrexate weekly . Treatment repeat every 8 week 9 course . Regimen B ( patient MRD day 36 regimen A ) ( closed 2/27/03 ) : Induction ( week 1-9 ) : Patients receive treatment induction regimen A . Consolidation ( week 10-19 ) : Patients receive treatment consolidation regimen A. Reinduction ( week 20-29 ) : Patients receive treatment reinduction regimen A nelarabine IV day 162-166 . Maintenance ( week 30-101 ) : Patients receive oral mercaptopurine daily day 1-28 36-56 ; oral methotrexate weekly ; nelarabine IV day 29-33 . Treatment repeat every 8 week 4 course . Beginning week 62 , patient receive vincristine IV ; oral prednisone three time daily 5 day ; oral mercaptopurine daily ; oral methotrexate weekly . Treatment repeat every 8 week 5 course . Regimen C ( poor prednisone responder stage 1 study patient enter stage 2 study ) ( closed 2/27/03 ) : Induction ( week 1-5 ) : Patients receive treatment induction ( week 1-5 ) regimen A nelarabine IV 1 hour day 29-33 . If bone marrow M1 , patient begin week 6 induction therapy day 36 peripheral blood count recover . If bone marrow M2 , patient begin week 6 induction therapy immediately . If bone marrow M3 , treatment discontinues . Induction ( week 6-9 ) : Patients receive treatment induction ( week 6-9 ) regimen A . Consolidation ( week 10-19 ) : Patients receive treatment consolidation regimen A. Reinduction ( week 20-29 ) : Patients receive treatment reinduction regimen B . Maintenance ( week 30-101 ) : Patients receive treatment maintenance regimen B . Regimen D ( effective 5/2004 ) : Induction ( week 1-5 ) : Patients receive vincristine IV day 1 , 8 , 15 ; oral prednisone 3 time day day 1-14 ; daunorubicin IV 15 minute day 1 , 8 , 15 , 22 ; nelarabine IV 1 hour day 29-33 ; asparaginase IM day 12 , 15 , 18 , 22 , 24 , 27 , 30 , 33 ; methotrexate IT day 1 . If bone marrow M1 , week 6 induction therapy begin day 36 peripheral blood count recover . If bone marrow M2 , patient begin week 6 induction therapy immediately . If bone marrow M3 , treatment discontinues . Induction ( week 6-9 ) : Patients receive cyclophosphamide IV 1 hour day 36 50 ; cytarabine IV SC day 36-39 , 43-46 , 50-53 , 57-60 ; oral mercaptopurine daily day 36-63 ; methotrexate IT day 43 57 . Patients poor responder prednisone induction therapy proceed regimen F. Patients good responder prednisone MRD induction therapy proceed regimen E. Patients good responder prednisone MRD induction therapy continue therapy regimen D. Consolidation ( week 10-19 ) : Patients must M1 marrow proceed . Patients receive oral mercaptopurine day 70-126 ; methotrexate IV 24 hour day 77 , 84 , 91 , 98 ; leucovorin calcium IV orally every 6 hour day 78-79 , 85-86 , 92-93 , 99-100 ; methotrexate IT day 77 , 84 , 91 , 98 . Reinduction ( week 20-29 ) : Patients &lt; 13 year old receive dexamethasone 3 time daily day 140-161 . Patients â‰¥ 13 year old receive oral dexamethasone day 140-146 155-161 ; nelarabine IV day 169-173 ; vincristine IV 15 minute day 140 , 147 , 153 ; pegaspargase IM day 143 ; cyclophosphamide IV day 176 ; cytarabine IV SC day 176-179 183-186 ; oral thioguanine day 176-189 ; methotrexate IT day 176 183 . Patients CNS disease undergo craniocervical radiotherapy begin day 196 continue 7-10 day . Maintenance ( week 30-61 ) : Patients receive oral mercaptopurine day 1-28 36-56 ; oral methotrexate day 1 , 8 , 15 , 22 , 36 , 43 , 50 ; nelarabine IV day 29-33 . Treatment repeat every 8 week 4 course . Maintenance ( week 62-101 ) : Patients receive vincristine IV day 1 ; oral dexamethasone twice daily day 1-5 ; oral mercaptopurine day 1-56 ; oral methotrexate day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 . Treatment repeat every 8 week 5 course . Regimen E ( good responder induction prednisone MRD ) ( effective 5/2004 ) : Patients receive consolidation therapy , reinduction therapy , maintenance therapy regimen D , nelarabine administer high dose . Regimen F ( poor responder induction prednisone ) ( effective 5/2004 ) : Patients receive nelarabine high dose induction therapy . Patients receive consolidation therapy , reinduction therapy , maintenance therapy regimen E. Patients follow monthly 1 year , every 2 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 100 patient ( 30 regimens A , B , C ; 70 regimen D , E , F ) accrue study within 9-29 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Newly diagnose Tcell acute lymphoblastic leukemia great 25 % bone marrow blast ( M3 ) Highrisk disease , define meeting least 1 follow criterion : WBC least 50,000/mm^3 Age 10 year Patients WBC least 25,000/mm^3 AND least 50 % peripheral blood blast eligible provide bone marrow aspiration contraindicate ( e.g. , patient eligible anesthesia sedation due respiratory distress secondary anterior mediastinal mass ) Concurrent registration POG 9900 within past 8 day require Performance status Karnofsky 50100 % ( 10 year age ) Performance status Lansky 50100 % ( 10 year age ) See Disease Characteristics Bilirubin great 1.5 mg/dL SGPT le 5 time normal Creatinine normal Creatinine clearance glomerular filtration rate least 60 mL/min No preexisting neuropathy grade 2 bad unless due leukemic infiltration Not pregnant nursing Fertile patient must use effective contraception No prior biologic therapy No 72 hour since prior intrathecal cytarabine No prior chemotherapy Prior steroid allow No chronic steroid treatment another disease Prior emergency radiotherapy mediastinum severe respiratory distress allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>